Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2021

Open Access 01-12-2021 | Endometrial Cancer | Primary research

Ninjurin 2 rs118050317 gene polymorphism and endometrial cancer risk

Authors: Yimin Cheng, Liting Yang, Guangyao Shi, Peng Chen, Liang Li, Hangrong Fang, Chao Chen

Published in: Cancer Cell International | Issue 1/2021

Login to get access

Abstract

Background

Endometrial cancer is one of the most common female reproductive system tumors. Ninjurin2 (NINJ2) is a new adhesion factor. As a vascular susceptibility gene, it is highly expressed in other cancers and promotes the growth of cancer cells. We conducted an association analysis between NINJ2 gene polymorphism and endometrial cancer risk.

Methods

Five SNPs rs118050317, rs75750647, rs7307242, rs10849390 and rs11610368 of NINJ2 gene were genotyped in 351 endometrial cancer patients and 344 healthy controls. The clinical index difference between cases and controls were tested by one-way analysis of variance. The allele and genotype frequency of cases and controls were been compared by Chi square test. The odds ratios (OR) with 95% confidence interval (95% CI) were examined by logistic regression analysis.

Results

The SNP rs118050317 mutant allele C and homozygote CC genotype were significant increased the endometrial cancer risk (OR 1.46, 95% CI 1.04–2.06, p = 0.028; OR 8.43, 95% CI 1.05–67.89, p = 0.045). In the clinical index analysis, there were significant higher quantities of CEA, CA125 and AFP in cases serum than controls.

Conclusion

The NINJ2 gene polymorphism loci rs118050317 mutant allele C was associated with an increased risk of endometrial cancer. CEA, CA125 and AFP quantities were significant higher in endometrial cancer patients.
Appendix
Available only for authorised users
Literature
1.
Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet (Lond Engl). 2005;366(9484):491–505.CrossRef
2.
Colombo N, Creutzberg C, Amant F, Bosse T, Gonzalez-Martin A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Int J Gynecol Cancer. 2016;26(1):2–30.PubMedCrossRef
3.
Lu Z, Chen J. Introduction of WHO classification of tumours of female reproductive organs, fourth edition. Zhonghua Bing li Xue Za Zhi Chin J Pathol. 2014;43(10):649–50.
4.
Gao Y, Zhao M, Dai X, Tong M, Wei J, Chen Q. The prevalence of endometrial cancer in pre- and postmenopausal Chinese women. Menopause (NY, NY). 2016;23(8):884–7.CrossRef
5.
Yoneda T, Kuboyama A, Kato K, Ohgami T, Okamoto K, Saito T, Wake N. Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer. Oncol Rep. 2013;30(1):25–34.PubMedPubMedCentralCrossRef
6.
Win AK, Reece JC, Ryan S. Family history and risk of endometrial cancer: a systematic review and meta-analysis. Obstet Gynecol. 2015;125(1):89–98.PubMedCrossRef
7.
Spurdle AB, Thompson DJ, Ahmed S, Ferguson K, Healey CS, O’Mara T, Walker LC, Montgomery SB, Dermitzakis ET, Fahey P, et al. Genome-wide association study identifies a common variant associated with risk of endometrial cancer. Nat Genet. 2011;43(5):451–4.PubMedPubMedCentralCrossRef
8.
De Vivo I, Prescott J, Setiawan VW, Olson SH, Wentzensen N, Attia J, Black A, Brinton L, Chen C, Chen C, et al. Genome-wide association study of endometrial cancer in E2C2. Hum Genet. 2014;133(2):211–24.PubMedCrossRef
9.
Cheng TH, Thompson DJ, O’Mara TA, Painter JN, Glubb DM, Flach S, Lewis A, French JD, Freeman-Mills L, Church D, et al. Five endometrial cancer risk loci identified through genome-wide association analysis. Nat Genet. 2016;48(6):667–74.PubMedPubMedCentralCrossRef
10.
Painter JN, Kaufmann S, O’Mara TA, Hillman KM, Sivakumaran H, Darabi H, Cheng THT, Pearson J, Kazakoff S, Waddell N, et al. A common variant at the 14q32 endometrial cancer risk locus activates AKT1 through YY1 binding. Am J Hum Genet. 2016;98(6):1159–69.PubMedPubMedCentralCrossRef
11.
Bienkiewicz J, Smolarz B, Malinowski A. Association between single nucleotide polymorphism +276G > T (rs1501299) in ADIPOQ and endometrial cancer. Pathol Oncol Res POR. 2016;22(1):135–8.PubMedCrossRef
12.
Bienkiewicz J, Romanowicz H, Malinowski A, Smolarz B. Association of single nucleotide polymorphism -2548 G/A (rs12112075) of leptin gene with endometrial cancer and uterine leiomyomas. Eur J Obstet Gynecol Reprod Biol. 2017;218:113–8.PubMedCrossRef
13.
Lin KP, Chen SY, Lai LC, Huang YL, Chen JH, Chen TF, Sun Y, Wen LL, Yip PK, Chu YM, et al. Genetic polymorphisms of a novel vascular susceptibility gene, Ninjurin2 (NINJ2), are associated with a decreased risk of Alzheimer’s disease. PLoS One. 2011;6(6):e20573.PubMedPubMedCentralCrossRef
14.
Zhu Y, Liu K, Tang X, Wang J, Yu Z, Wu Y, Chen D, Wang X, Fang K, Li N, et al. Association between NINJ2 gene polymorphisms and ischemic stroke: a family-based case-control study. J Thromb Thrombolysis. 2014;38(4):470–6.PubMedPubMedCentralCrossRef
15.
Zhang Z, Ni G, Xu G, Xu J, Liu X. A novel functional polymorphism in the NINJ2 promoter predicts risk of large artery atherosclerotic stroke. Mol Neurobiol. 2016;53(10):7178–83.PubMedCrossRef
16.
Delahanty RJ, Xiang YB, Spurdle A, Beeghly-Fadiel A, Long J, Thompson D, Tomlinson I, Yu H, Lambrechts D, Dork T, et al. Polymorphisms in inflammation pathway genes and endometrial cancer risk. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cospons Am Soc Prev Oncol. 2013;22(2):216–23.CrossRef
17.
Shi C, van der Wal HH, Silljé HHW, Dokter MM, van den Berg F, Huizinga L, Vriesema M, Post J, Anker SD, Cleland JG, et al. Tumour biomarkers: association with heart failure outcomes. J Intern Med. 2020;288(2):207–18.PubMedPubMedCentralCrossRef
18.
Samy N, Ragab HM, El Maksoud NA, Shaalan M. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up. Cancer Biomark Sect A Dis Mark. 2010;6(2):63–72.CrossRef
19.
Li S, Jin T, Zhang J, Lou H, Yang B, Li Y, Chen C, Zhang Y. Polymorphisms of TREH, IL4R and CCDC26 genes associated with risk of glioma. Cancer Epidemiol. 2012;36(3):283–7.PubMedCrossRef
20.
Yuan LJ, Jin TB, Yin JK, Du XL, Wang Q, Dong R, Wang SZ, Cui Y, Chen C, Lu JG. Polymorphisms of tumor-related genes IL-10, PSCA, MTRR and NOC3L are associated with the risk of gastric cancer in the Chinese Han population. Cancer Epidemiol. 2012;36(6):e366–72.PubMedCrossRef
21.
Li G, Bai M, Guo C, Zhu L, Wang L, Yuan D, Jin T, He Y. Association analysis of CHRNA3 polymorphisms with schizophrenia in a Chinese Han population: a case-control study. Medicine. 2018;97(23):e10863.PubMedPubMedCentralCrossRef
22.
Araki T, Milbrandt J. Ninjurin2, a novel homophilic adhesion molecule, is expressed in mature sensory and enteric neurons and promotes neurite outgrowth. J Neurosci. 2000;20(1):187–95.PubMedPubMedCentralCrossRef
23.
Wang X, Zhang J, Liu Y, Zhang Y. Relationship between nerve injury-induced protein gene 2 polymorphism and stroke in Chinese Han population. J Biomed Res. 2011;25(4):287–91.PubMedPubMedCentralCrossRef
24.
Ahn BJ, Lee HJ, Shin MW, Choi JH, Jeong JW, Kim KW. Ninjurin1 is expressed in myeloid cells and mediates endothelium adhesion in the brains of EAE rats. Biochem Biophys Res Commun. 2009;387(2):321–5.PubMedCrossRef
25.
Trabert B, Eldridge RC, Pfeiffer RM, Shiels MS, Kemp TJ, Guillemette C, Hartge P, Sherman ME, Brinton LA, Black A, et al. Prediagnostic circulating inflammation markers and endometrial cancer risk in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. Int J Cancer. 2017;140(3):600–10.PubMedCrossRef
26.
Wang J, Fa J, Wang P, Jia X, Peng H, Chen J, Wang Y, Wang C, Chen Q, Tu X, et al. NINJ2—A novel regulator of endothelial inflammation and activation. Cell Signal. 2017;35:231–41.PubMedCrossRef
27.
Che Q, Liu BY, Wang FY, He YY, Lu W, Liao Y, Gu W, Wan XP. Interleukin 6 promotes endometrial cancer growth through an autocrine feedback loop involving ERK-NF-kappaB signaling pathway. Biochem Biophys Res Commun. 2014;446(1):167–72.PubMedCrossRef
Metadata
Title
Ninjurin 2 rs118050317 gene polymorphism and endometrial cancer risk
Authors
Yimin Cheng
Liting Yang
Guangyao Shi
Peng Chen
Liang Li
Hangrong Fang
Chao Chen
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2021
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-01646-5

Other articles of this Issue 1/2021

Cancer Cell International 1/2021 Go to the issue

Primary Research

HPV E6/E7 mRNA in situ hybridization in endocervical adenocarcinoma: implications for prognosis and diagnosis

Review

The effective function of circular RNA in colorectal cancer

Primary research

Identification of four genes and biological characteristics of esophageal squamous cell carcinoma by integrated bioinformatics analysis

Primary research

LncRNA ASAP1-IT1 enhances cancer cell stemness via regulating miR-509-3p/YAP1 axis in NSCLC

Primary research

Combating drug resistance in acute myeloid leukaemia by drug rotations: the effects of quizartinib and pexidartinib

Primary research

Quantitative phosphoproteomic analysis reveals chemoresistance-related proteins and signaling pathways induced by rhIL-6 in human osteosarcoma cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits